COVID-19 - April 9, 2022
Aarhus professor to head European coronavirus research project
Professor Trine Hyrup Mogensen from Aarhus University will study why some people suffer from serious COVID-19 infections, while others do not become ill at all, even when exposed to massive infection. Hyrup Mogensen, who is a professor at the Department of Biomedicine and a medical doctor at the Department of Infectious Diseases at Aarhus University […]
COVID-19 - April 9, 2022
Alpaca nanobodies potently neutralize SARS-CoV-2 variants
Researchers at Karolinska Institutet have developed a new strategy for identifying potent miniature antibodies, so-called nanobodies, against emerging SARS-CoV-2 variants. The approach led to the discovery of multiple nanobodies that in cell cultures and mice effectively blocked infection with different SARS-CoV-2 variants. “With the help of advanced laboratory techniques, we were able to identify a […]
COVID-19 - April 7, 2022
Sweden’s first COVID-19 vaccine facility inaugurated
Sweden’s Minister of Health and Social Affairs, Lena Hallengren, has officially inaugurated Valneva Sweden’s new COVID-19 vaccine manufacturing facility, the first and only one of its kind in Sweden. “The fact that COVID-19 vaccines are manufactured in Sweden is a progress that indicate the strength of the Swedish model where companies and the society cooperate […]
COVID-19 - March 30, 2022
KeyPlants ships vaccine manufacturing facility to Senegal
KeyPlants has shipped a first-of-its-kind vaccine manufacturing filling facility to Senegal in West Africa. After the facility is installed and becomes fully operational later in 2022, it will be the only regional manufacturing hub on the continent outside of South Africa capable of producing finished COVID-19 and other life-saving vaccines, states KeyPlants. “We are proud […]
COVID-19 - March 28, 2022
AstraZeneca’s Evusheld approved in the EU
AstraZeneca’s Evusheld, a long-acting antibody combination, has been granted marketing authorization in the European Union (EU) for the pre-exposure prophylaxis (prevention) of COVID-19 in a broad population of adults and adolescents aged 12 years and older weighing at least 40 kg. The approval by the European Commission was based on results from the Evusheld clinical […]
COVID-19 - March 25, 2022
AstraZeneca’s Evusheld recommended for approval in the EU
AstraZeneca’s Evusheld, a long-acting antibody combination, has been recommended for marketing authorization in the EU for the pre-exposure prophylaxis (prevention) of COVID-19 in a broad population of adults and adolescents aged 12 years and older weighing at least 40 kg. People not adequately protected by a COVID-19 vaccine may particularly benefit from pre-exposure prophylaxis with […]
